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KIRITSY-ROY, J. A., S. M. STANDISH AND L. C. TERRY. Dopamine D-1 and D-2 receptor antagonists- potentiate analgesic and 
motor effects of morphine. PHARMACOL BIOCHEM BEHAV 32(3) 717-721, 1989.--To examine the role of dopamine receptor 
subtypes mediating analgesic and motor responses to opioids, rats were pretreated with either saline or a selective D-1 or D-2 dopamine 
receptor antagonist 10 min prior to morphine (12 mg/kg IP). Analgesic response latency was determined using the hot plate test (52.5°C 
and 55°C), and catalepsy was assessed using the abnormal posture test. Morphine increased analgesic response latency to 44,5 _+ 7.9% 
of the maximum possible response, but had no cataleptic effect in the abnormal posture test. Pretreatment with either the D-I 
antagonist, SCH 23390 (50-100 Ixg/kg), or the D-2 antagonist, eticlopride (20-150 ixg/kg), potently enhanced morphine analgesia as 
measured on the 52.5°C hot plate. Peak analgesic responses to morphine increased to 100_+ 0% and 91.9-+ 7.5% of maximum with 
the highest doses of SCH 23390 and eticlopride, respectively. These treatments also produced catalepsy. Increasing the hot plate 
temperature to 55°C reduced response latency in groups treated with either dopamine receptor antagonist plus morphine. This indicates 
that the animals were capable of responding at a shorter latency and demonstrates that motor impairment cannot account for 
potentiation of morphine analgesia by D-I and D-2 antagonists at 52.5°C. These results show that the relationship between dopamine 
and opioids with respect to analgesic and motor systems involves both dopamine receptor subtypes. 
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Opioid-dopamine interactions 
BRAIN dopaminergic systems have been widely implicated in 
many of the pharmacologic effects of opioids. Manipulations 
which alter the activity of dopamine in the central nervous system 
frequently shift analgesia dose-response curves for morphine and 
other opioid drugs. For example, the dopamine antagonist, halo- 
peridol, while not analgesic itself, potentiated the analgesic 
response to morphine in mice (7) and in rats (13). Other dopamine 
receptor blockers, such as spiroperidol, clothiapine and perphena- 
zine, reduced the analgesic EDso for morphine in mice (27). 
Destruction ofdopamine neurons by treatment with 6-hydroxydopamine 
enhanced morphine analgesia in both the hot plate and tail 
compression tests in rats (21). Although the dopamine receptor 
agonist, apomorphine, had no effect on morphine-induced anti- 
nociception in naive rats, it blocked completely morphine analge- 
sia in chronically haloperidol-treated rats (13). Similarly, apomorphine 
shifted to the right the dose-response curve for morphine-induced 
antinociception in naive mice (27). Thus, it appears that the 
opioid-sensitive pain pathway is under the inhibitory influence of 
dopamine. 
In recent years, compelling evidence has accumulated to allow 
classification of CNS dopamine receptors into two distinct sub- 
types, designated D-1 and D-2, on the basis of biochemical and 
pharmacological criteria. It is generally agreed that the D-1 
receptor is coupled to adenylate cyclase, and stimulation causes 
increased production of cAMP (14). Stimulation of the D-2 
receptor has either no effect on cAMP formation or reduces cAMP 
accumulation induced by D- 1 agonists (26). The recent availability 
of selective agonists and antagonists for dopamine D-1 and D-2 
receptors provides powerful tools which can be used to determine 
the roles of these receptor subtypes in mediating some of the 
physiological and pharmacological effects of dopamine in the 
CNS. The experiments described here were undertaken to provide 
insight into the role of specific dopamine receptor subtypes in 
mediating analgesic and motor responses to morphine in rats. SCH 
23390 was employed as a selective D-1 antagonist (11,12), and 
eticlopride was used to produce antagonism at the D-2 receptor 
(6). The results indicate that both D-1 and D-2 receptors are 
involved in analgesic and motor effects of opioids. 
~Requests for reprints should be addressed to Judith A. Kiritsy-Roy, Ph.D., Veterans Administration Medical Center (151), 2215 Fuller Road, Ann 
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METHOD 
Adult male Sprague-Dawley rats (Harlan Ind., Indianapolis, 
IN) weighing 306_+5 g ( n =  123) were used in all experiments. 
Animals were housed in groups of 4-5  in the animal quarters, with 
automatically controlled lighting (lights on from 7:00 a .m.-7:00 
p.m.),  temperature (22°C) and humidity. Food and water were 
available ad lib except the night before the experiment, when 
subjects were food and water deprived for 16-20 hours. The rats 
were moved from the animal facility to the laboratory on the 
morning of experimentation. 
Analgesia was assessed using an adaptation of the hot plate. 
procedure described by O'Callaghan and Holtzman (17). Their 
studies demonstrated that reduction of hot plate temperature from 
55°C was necessar,v to achieve optimum sensitivity for detection of 
analgesic activity of opioid-related drugs. The device consisted of 
a copper surface maintained at a temperature of either 52.5°C or 
55°C. A clear Plexiglas cylinder 10" in height with a 12" diameter 
confined the rat to the heated surface. Endpoints used to determine 
reaction latency were licking of a hindpaw or jumping to the rim 
of the cylinder. A maximum cut-off time of 45 sec was used to 
prevent tissue trauma to analgesic rats. Three baseline latency 
determinations on the hot plate were obtained at 5-rain intervals 
before administration of drug, and these were averaged to give a 
mean baseline latency (B). Posttreatment response latencies (R) 
were observed every 5 rain for 30 rain, and a final determination 
was made at 40 rain. Analgesic responses are calculated as the 
percent of the maximum possible response (%MPR), defined as 
[(R - B)/(45 - B)] × 100%. 
The presence of a state of catalepsy was detected using the 
abnormal posture test (8). This test involved placement of the 
hindpaw of the rat upon a 3-cm high cork. Latency to step-down 
was recorded before and at intervals after drug treatment. A 
maximum cut-off time of 45 sec was used, and cataleptic re- 
sponses were calculated using the same formula for %MPR 
described above for analgesic responses. 
All drugs were administered IP, and dosages are given as 
weight of the salt form. SCH 23390 hydrochloride (RBI, Natick, 
MA) was initially dissolved in a minimum volume of 10% acetic 
acid and diluted with saline. Morphine sulfate (Wyeth, Philadel- 
phia, PA, 10 mg/ml) was administered at a dose of 12 mg/kg. 
Either SCH 23390 hydrochloride or eticlopride hydrochloride 
(RBI, Natick, MA) was injected 10 min before morphine in a 
volume of 1 ml/kg. 
Data were analyzed by ANOVA using SAS on an IBM PC/AT. 
Differences between treatments were considered significant for 
p < 0 . 0 5  as determined with Duncan's  multiple comparisons test. 
RESULTS 
Effect of SCH 23390 on Morphine Analgesia 
Injection of saline (1 ml/kg) had no effect on response latency 
on the 52.5°C hot plate. Morphine (12 mg/kg) produced a 
significant increase in latency compared to saline control (Fig. 
IA). The analgesic effect of morphine peaked by 30 rain after 
treatment and was antagonized by naloxone (1 mg/kg) injected 10 
rain before morphine (data not shown). The D-1 receptor antago- 
nist, SCH 23390, potentiated the analgesic response to morphine 
(12 mg/kg) (Fig. 1A). Potentiation of morphine-induced analgesia 
by SCH 23390 was dose-related over the dose range of 50-100 
~g/kg. These doses of SCH 23390 administered alone to groups of 
rats had little antinociceptive activity, although a higher dose of 
400 ~,g/kg produced a transient analgesic response that peaked at 
15 rain and returned to baseline by 30 rain (Fig. 1B). 
Effect of Eticlopride on Morphine Analgesia 
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FIG. 1. Analgesic responses on the 52.5°C hot plate following adminis- 
tration of SCH 23390 (SCH) in combination with morphine (Mor) (A) or 
alone (B). (A) SCH (100 ~g/kg, n = 7 or 50 ~g/kg, n = 6) was injected 10 
min before Mot (12 mg/kg), which was injected at Time=0. Additional 
groups of rats received saline injection 10 min before saline (n = 6) or Mor 
( 12 mg/kg, n = 17) at Time = 0. (B) Doses of SCH were injected in groups 
of 6 rats per dose at Time =0. Three baseline latency determinations were 
obtained at 5-min intervals before the pretreatment with saline or SCH and 
these were averaged. The average baseline latency did not differ among 
groups and was 10.4 _+ 0.4 sec. Analgesic responses are expressed as mean 
percent of the maximum possible response ±SEM (45 sec cut-off). 
*p<0.05 compared to saline; +p<0.05 compared to Mor. 
related potentiation of the analgesic effect of morphine (Fig. 2A). 
The peak analgesic effect of morphine (12 mg/kg) increased from 
approximately 45% MPR to 69% after 75 p,g/kg and to 92% after 
150 p,g/kg eticlopride. A smaller dose of eticlopride (20 p,g/kg) 
had no significant effect on morphine-induced analgesia (data not 
shown). Doses of eticlopride that potentiated the morphine re- 
sponse were themselves completely devoid of analgesic activity, 
although a higher dose (300 p,g/kg) produced a small analgesic 
response (Fig. 2B). 
Cataleptic Responses to Morphine Following Pretreatment With 
D-I or D-2 Antagonists 
Administration of morphine (12 mg/kg) had no apparent 
cataleptic effect up to 30 rain after treatment, as assessed by the 
abnormal posture test (Fig. 3A). SCH 23390 (100 Ixg/kg) alone 
produced no significant change in cataleptic behavior until 40 rain 
after its administration (Fig. 3A). Similarly, the small cataleptic 
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FIG. 2. Analgesic responses on the 52.5°C hot plate followin@ adminis- 
tration o f  eticlopride (Etc) in combination with mo~h ine  (Mor)  (A) or 
alone (B). (A) Etc (75 #g/kg, n = 7  or ]50 ~g/kg, n=7 )  was injected 10 
min before Mot  (12 mg/kg), which was injected at T ime=0.  Additional 
groups of rats received a saline injection ]0 rain before saline (n = 6) or 
Mor (n = 17) at Time =0.  (B) Doses of Etc were injected in groups of 5-6 
rats at T ime=0.  Baseline and response latencies were determined as 
described in the legend to Fig. 1. *p<O.05 compared to saline; +p<0.05 
comp~ed to Mot. 
response to eticlopride (150 t-~g/kg) was delayed until 30-40 min 
posttreatment (Fig. 3B). Pretreatment of rats with these same 
doses of SCH 23390 (Fig. 3A) or eticlopride (Fig. 3B) 10 min 
prior to morphine (12 mg/kg) elicited profound cataleptic behav- 
ior. Enhancement was noted by 15 min after morphine, and 
subsequently reached nearly 100% MPR with either dopamine 
antagonist. 
Effect of Thermal Stimulus Intensi~ on D-1/D-2 Antagonist- 
Enhanced Morphine Analgesia 
Since the hot plate test for analgesia requires the animal to 
perform a coordinated motor response, treatments which produce 
motor impairment might appear as analgesic. To determine if 
animals treated with morphine plus either SCH 23390 or eticlo- 
pride were capable of initiating the appropriate motor response 
when tested for analgesia, groups of rats were tested on the hot 
plate set at a higher temperature (55°C). A decline in reaction 
latency at 55 ° compared to 52.5 ° indicates that motor responses are 
not impaired by the drug treatment (10). As shown in Fig. 4, 
neither SCH 23390 nor eticlopride administered prior to morphine 
prolonged response latency on the 55°C hot plate compared to the 
group treated with morphine alone. This contrasts with the 
pronounced enhancement of morphine analgesia by these drugs at 
52.5 °, as described above. These results indicate that although the 
rats become cataleptic with the combined drug treatment, they are 
capable of responding to the nociceptive stimulus at a latency 
similar to that seen in animals that are not cataleptic. 
D I S C U S S I O N  
These studies were designed to examine the involvement of 
D-1 and D-2 dopamine receptor subtypes mediating analgesic and 
motor effects of morphine in rats. We used potent and selective 
D-I and D-2 receptor antagonist drugs in combination with 
morphine and found that antagonism of either dopamine receptor 
subtype potentiates morphine analgesia and produces profound 
catalepsy. Previous reports have described potentiation of opioid 
effects by D-2 dopamine receptor antagonists. Haloperidol, spiro- 
peridol, clothiapine and perphenazine have been reported to 
enhance opioid analgesia in rats and mice (7,27). However, until 
recently, the lack of selective D-I receptor antagonists has 
precluded direct assessment of the significance of this receptor in 
dopaminergic function. 
SCH 23390 binds with high affinity to brain dopamine recep- 
tors, with a K a less than 1 nM (3, 24, 25). Whereas it inhibits the 
binding of [3H]-piflutixol to striatal membranes with a K~ of 1 to 
1.3 nM (11,16), K i values for displacement of [3H]-haloperidol 
and [3H]-spiperone binding at D-2 receptors by SCH 23390 are at 
least one order of magnitude higher, indicating that this benz- 
azepine derivative is selective for the D-I dopamine site. In 
addition, SCH 23390 potently inhibits dopamine-stimulated cAMP 
formation in homogenates of striatum with an IDso of 11 nM(12), 
but has no effect on pituitary prolactin secretion except at doses in 
excess of 2.5 mg/kg IP (1). 
Recently, dePaulis et al. (6) reported the synthesis of a potent 
and selective D-2 receptor antagonist, eticlopride. The eticlopride 
ICeD for inhibition of [3H]-spiperone binding to D-2 sites is 0.92 
nM (6) compared to more than 100 I~M for inhibition of [3H]- 
flupenthixol binding to the D-1 receptor (9). Eticlopride also 
inhibits apomorphine-induced hyperactivity with an ED,so of 9-12 
t~g/kg and stereotypy with an EDso of 75 gg/kg (6,15). To 
evaluate the role of D- 1 and D-2 dopamine receptors in the opioid 
analgesic system, we used SCH 23390 and eticlopride at doses 
which selectively antagonize D-l  and D-2 receptors, respectively. 
Both SCH 23390 and eticlopride strongly potentiated the 
analgesic response to morphine in rats. These effects were 
dose-related for both drugs. The lower dose of SCH 23390 (50 
t~g/kg) had no analgesic activity when administered alone, but 
significantly potentiated morphine analgesia; the higher dose (100 
l, zg/kg) itself produced a small increase in response latency at 
20-25 min after its administration. Doses of eticlopride that were 
completely devoid of analgesic activity on their own also signifi- 
cantly potentiated morphine-induce analgesia. The D-1 antagonist 
appeared to be somewhat more potent than the D-2 antagonist, 
since SCH 23390 (100 I,~g/kg IP), a dose equivalent to 0.25 
~mol/kg, produced maximum analgesia in all rats subsequently 
treated with morphine 12 mg/kg, whereas the highest dose of 
eticlopride (0.4 i~mol/kg) potentiated the morphine effect to about 
90% of maximum. However, SCH 23390 and eticlopride appear to 
interact in a qualitatively similar manner with morphine, in spite of 
their high selectivities for D-1 and D-2 receptors, respectively. 
We also found that either SCH 23390 or eticlopride adminis- 
tered in combination with morphine produced strong catalepsy. 
The cataleptic responses to either dopamine antagonist alone were 
relatively small, and morphine alone produced no catalepsy at the 
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FIG. 3. Cataleptic effects of SCH 23390 (A) and eticlopride (B) alone and 
in combination with morphine. Catalepsy was assessed using the cork test 
(8). Three baseline determinations were made at 5-min intervals before 
injection of SCH 23390 (SCH) or eticlopride (Etc); morphine (Mot) or 
saline was injected 10 rain later at Time =0. Responses are expressed as 
mean percent of the maximum possible response -+ SEM (45 sec cut-off) 
for groups of 5 rats. *p<0.05 compared to saline. 
dose used (12 mg/kg). Although higher doses of morphine are 
reported to induce a cataleptic state, this catalepsy differs quali- 
tatively from that induced by neuroleptic drugs (5,20). Neverthe- 
less, it is thought that opioid systems in the striatum interact with 
dopaminergic nigrostriatal neurons to alter motor behavior. It has 
been suggested that opioids reduce nigrostriatal dopamine neuro- 
transmission by presynaptic inhibition of dopamine release (2). 
Dopamine D-1 and D-2 receptors have been localized in rat 
neostriatum (4), and our results may reflect interactions between 
morphine and the D-l  and D-2 antagonists in this brain region. 
Because the combination of either SCH 23390 or eticlopride 
with morphine produced profound inhibition of locomotion, it 
appeared that the motor effect itself may account for or contribute 
to the prolonged hot plate response latencies in groups treated with 
morphine plus a dopamine antagonist. To assess the role of motor 
impairment, the stimulus intensity was increased from 52.5°C to 
55°C. This increase in hot plate temperature resulted in a fall in 
response latency in groups treated with morphine plus SCH 23390 
or eticlopride. In fact, response latencies at 55°C in these groups 
approached those observed in the group treated with morphine 
alone. This result indicates that although animals treated with 
morphine and a dopamine receptor antagonist exhibit inhibition of 
locomotion, they are fully capable of initiating an appropriate 
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FIG. 4. Analgesic responses to morphine (Mor) on the 55°C hot plate 
following D-1 or D-2 dopamine receptor antagonist pretreatment. Saline, 
SCH 23390 (SCH, 100 Ixg/kg, n =5) or eticlopride (Etc, 75 t~g/kg) was 
injected 10 rain before Mot (12 mg/kg), which was injected at Time=0. 
A control group of 5 rats received 2 injections of saline (1 ml/kg) spaced 
10 min apart. Baseline and response latencies were determined as 
described in the legend to Fig. 1. The average baseline latency for all 
groups on the 55°C hot plate was 6.5 _+ 0.3 sec. 
motor response to the stimulus at a latency similar to animals 
without motor impairment. Although this experiment does not rule 
out the possibility that dopamine antagonists enhance opioid 
analgesia by an effect on the motor component of the pain system, 
it demonstrates that motor impairment per se cannot account for 
the apparent enhancement of morphine analgesia by D-1 and D-2 
antagonists. 
It is interesting to note that other behavioral effects of D-1 and 
D-2 antagonists have been difficult to dissociate, suggesting a 
functional interaction between the D-I and D-2 receptors. It has 
been hypothesized that in brain regions containing both D-1 and 
D-2 dopamine receptors, D-1 receptors modulate behavioral re- 
sponses initiated by D-2 receptor stimulation (19).The opioid- 
dopamine synergy reported here may reflect an interaction between 
these systems in a brain region containing a mixed population of 
dopamine receptors. Alternatively, since opioids elicit antinocicep- 
lion at several levels of the neuraxis (18,28), morphine may 
interact with a D-1 mechanism at one level and with D-2 pathways 
at another. 
Preliminary studies indicated that D-1 or D-2 receptor agonists 
did not attenuate the analgesic response to morphine, as might 
have been predicted from the results with the dopamine antago- 
nists (data not shown). This finding is similar to that reported by 
Kamata and co-workers (13), which shows that apomorphine had 
no effect on morphine analgesia except in rats treated chronically 
with haloperidol. The inability of dopamine agonists to modulate 
opioid analgesia could be interpreted in several ways. 1) Dopa- 
mine receptor antagonists might produce their effects by a non- 
dopaminergic mechanism. Although SCH 23390 binds to a 5- 
hydroxytryptamine (5-HT) site in vitro, its affinity for the D-1 site 
is about 25 times higher than for 5-HT (11). Moreover, doses of 
SCH 23390 from 40-200 Ixg/kg had no inhibitory effect on the 
typical serotonergic behavioral syndrome induced by 5-methoxy- 
N,N-dimethyltryptamine (19). Thus, it is unlikely that a seroto- 
nergic mechanism is involved in potentiation of opioid analgesia 
by SCH 23390, since doses used in these studies were less than 
200 Ixg/kg. Eticlopride displays little affinity for serotonergic, 
adrenergic, histaminergic or muscarinic receptors in vitro (9). 2) 
The dopaminergic system interacting with the opioid analgesic 
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mechanism might be maximally activated under basal condit ions,  
rendering dopaminergic  agonists apparently ineffective against 
morphine.  As suggested by Kamata  and co-workers  (13), inhibi- 
tion of  opioid analgesia by dopamine agonists may only be 
unmasked by treatments,  such as chronic neuroleptic administra- 
tion, which cause up-regulation of  doamine receptors and conse- 
quently a supersensitivity of  the dopamine system, 
Recently,  Schoffelmeer  and co-workers  have demonstrated that 
opioids inhibit dopamine-st imulated c A M P  release from slices of  
rat neostriatum (22,23). The effect  o f  delta opioid agonists is 
strongly protentiated in the presence of  sulpiride, a D-2 selective 
antagonist.  The authors suggest that D-2 receptor antagonism in 
neostriatum enhances  the inhibitory effect on c A M P  of  delta, but 
not mu, opioids by inducing a coupling between the delta opioid 
receptor and dopamine-sensi t ive adenylate cyclase.  Although 
sulpiride had no effect on morphine ' s  inhibitory effect  on dopa- 
mine- induced c A M P  release from striatal slices, it is interesting to 
speculate that a similar coupling may occur between the analgesic 
and cataleptic mu-opioid receptors and adenylate cyclase in other 
brain regions,  which might account for the enhanced analgesic and 
cataleptic effects of  morphine in the presence of  D-1 or D-2 
receptor antagonists reported here. 
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